Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer

NCT02178436 is registered in ClinicalTrials.gov with Mohammed Najeeb Al Hallak as lead sponsor.

NCT NCT02178436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02178436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Mohammed Najeeb Al Hallak
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2014
Completion date
April 5, 2023
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acinar cell adenocarcinoma of the pancreas, duct cell adenocarcinoma of the pancreas, stage iv pancreatic cancer